Better Context → Better Decisions
Context counts in life sciences. The FENIX analyst team is tirelessly using its experience to put you in a position to succeed. Below, our readers without corporate access will find a wealth of contextualized life science insight ready to be purchased in the FENIX Marketplace. If our content sharing limitations are inconvenient for you, reach out to Brady for unlimited corporate, institutional, or individual access.
$599
Posted in: Basal Insulin, Bolus Insulin, Glucose Monitoring, Insulin Delivery, Other May 05 | 2021Tandem, Lannett, Esperion, and Ionis Q1 '21 Earnings Updates; Nemaura Receives Order for its Non-invasive CGMPurchase Blast
$599
Posted in: Basal Insulin, Bolus Insulin, GLP-1RA May 05 | 2021Novo Nordisk Q1 '21 Earnings UpdatePurchase Blast$599
Posted in: Basal Insulin, Bolus Insulin, GLP-1RA May 04 | 2021New Dual GLP-1/GIP RA from Carmot Receives IND; Lilly ESG Strategy Highlights; Pfizer Q1 '21 Earnings UpdatePurchase Blast
$599
Posted in: Glucagon, Other May 03 | 2021Zealand Ph3 RTU Dasiglucagon Results Published in Diabetes Care; Genfit Launches NASHnext Diagnostic TestPurchase Blast
$599
Posted in: Basal Insulin, Glucagon, Insulin Delivery, SGLT2i Apr 30 | 2021Lilly Ph4 Basal Insulin Titration Trial; Lilly Ph2 GGG Tri-agonist Trial; AZ Q1 '21 Earnings Update; Xeris's Ogluo Receives UK MHRA ApprovalPurchase Blast$599
Posted in: Basal Insulin, Bolus Insulin, DPP-IVi, Glucose Monitoring, Other Apr 29 | 2021Dexcom, Teladoc, Amarin, Biocon, and Merck Q1 '21 Earnings Updates; Abbott Libre 3 User ReviewsPurchase Blast
$599
Posted in: Basal Insulin, Bolus Insulin, GLP-1RA, Glucose Monitoring, Other Apr 28 | 2021Welldoc Receives New Patent; Nemaura Shareholder Update; Sanofi and Teva Q1 '21 Earnings UpdatesPurchase Blast
$599
Posted in: Dual/triple agonist, Other Apr 27 | 2021Lilly and Novartis Q1 '21 Earnings Updates; New Trulicity TV DTC; Provention Meets with FDAPurchase Blast
$599
Posted in: Other Apr 22 | 2021Better Therapeutics First Patient Enrolled in BT-001 Trial for T2DM; ProtoKinetix Resumes Islet Ph1 Trials in T1DM; Amarin Receives Great Britain Marketing Authorization Approval for Vazkepa CV Risk ReductionPurchase Blast$599
Posted in: Basal Insulin, Bolus Insulin, Glucose Monitoring, Other Apr 21 | 2021Novo to Initiate Oral Sema Ph3a Obesity Program; Integrity Applications Appoints David Klonoff to Scientific Advisory Board; Roche, Poxel, and Adocia Q1 '21 Earnings UpdatesPurchase Blast
$599
Posted in: Dual/triple agonist, GLP-1RA Apr 21 | 2021Heart Failure: Tirzepatide vs. Semaglutide HFpEF Ph3 Trial AnalysisPurchase Blast
$599
Posted in: Glucose Monitoring, Other, SGLT2i Apr 20 | 2021Novo QW Icodec Ph3 T1DM Trial Initiated; Dexcom G6 Approved for Upper Arm Wear in Canada; Dario Launches Virtual Health Initiative with MediOrbis; J&J and Abbott Q1 '21 Earnings UpdatesPurchase Blast
$599
Posted in: Basal Insulin, Bolus Insulin, DPP-IVi, GLP-1RA, SGLT2i Apr 19 | 2021April 19-22 CHMP Agenda; EMPEROR-REDUCED Opinion?; Virta Health Raises $133M in Series EPurchase Blast
$599
Posted in: Basal Insulin, Bolus Insulin, Glucose Monitoring, Insulin Delivery Apr 19 | 2021Insulet Omnipod 5 Tale-of-the-tape AnalysisPurchase Blast
$599
Posted in: GLP-1RA, Other Apr 16 | 2021Ozempic 4-dose Pen Back in the Label; Diamyd to Initiate DIAGNODE-3 Trial "Later This Year"; Nemaura Appoints New Global Head of Digital ProgramsPurchase Blast
$599
Posted in: Insulin Delivery Apr 14 | 2021Medtronic 7-day Infusion Set Launched in EU; New Medtronic Sensor+Infusion Set Combination TrialPurchase Blast
$599
Posted in: Basal Insulin, Bolus Insulin, Dual/triple agonist, GLP-1RA, Glucose Monitoring, Insulin Delivery, Other Apr 13 | 2021New BI/Zealand Trials in NASH and Obesity; vTv Granted BTD for TTP399; Jaguar Gene Therapy $139M Series B; CeQur $115M Series C5; Nemaura Launches BEATdiabetes App and proBEAT CGM Pilot; BioCorp/Roche Launch Mallya in France; Amarin CEO to RetirePurchase Blast
$599
Posted in: Basal Insulin, Bolus Insulin, Glucose Monitoring Apr 12 | 2021Novo Connected Pens Now Integrate with mySugr; Abbott Partners with Olympic Runner for Libre Sense Glucose Biosensor; New Non-invasive Glucose Monitoring Meter?Purchase Blast
$599
Posted in: Basal Insulin, Bolus Insulin, Glucose Monitoring, Other Apr 08 | 2021Provention Bio Delay Appears Inevitable; Better Therapeutics To Go Public; Dexcom G6 Direct Distribution in the Netherlands; Sanofi Furthers Social Responsibility Outreach; Medtronic Commits to Three Initiatives to Address Healthcare Equity; Expanded Access to CGM and Insulin Pumps in CanadaPurchase BlastGet the Latest Analysis
Stay informed and aligned with frequent updates to keep a pulse on the industry.
If you already have an account, please log in. If you have any questions or would like to subscribe to our services, please contact Brady.
